Antigen presented by tumors in vivo determines the nature of CD8 + T-cell cytotoxicity

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6615-6623

  Shanker, Anil ^a,b   Brooks, Alan D ^a,b   Jacobsen, Kristen M ^a   Wine, John W ^a   Wiltrout, Robert H ^a   Yagita, Hideo ^c   Sayers, Thomas J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; T LYMPHOCYTE RECEPTOR; VIRUS HEMAGGLUTININ;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IN VIVO STUDY; INFLUENZA VIRUS; KIDNEY CARCINOMA; LYMPHOCYTOTOXICITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR REJECTION;

ANIMALS; ANTIGEN PRESENTATION; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS;

EID: 69249116526     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0685     Document Type: Article

References (34)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
2. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576-83.
3. Sayers TJ, Brooks AD, Lee JK, et al. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol 1998;161:3957-65.
4. Smyth MJ, Kelly JM, Sutton VR, et al. Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001; 70:18-29.
5. Henkart PA, Catalfamo M. CD8+ effector cells. Adv Immunol 2004;83:233-52.
6. Sayers TJ, Brooks AD, Seki N, et al. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukoc Biol 2000;68:81-6.
7. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369: 31-7.
8. van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-90.
9. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-60.
10. Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-g mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 2000;165:7116-24.
11. Seki N, Brooks AD, Carter CR, et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002;168:3484-92.
12. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999;163:4462-72.
13. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998;160:643-51.
14. Morgan DJ, Liblau R, Scott B, et al. CD8(+) T cellmediated spontaneous diabetes in neonatal mice. J Immunol 1996;157:978-83.
15. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999;163:4335-41.
16. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beamradiation of tumors alters phenotype of tumor cells to render themsusceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64: 4328-37.
17. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984;159:1-20.
18. Seki N, Hayakawa Y, Brooks AD, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 2003;63:207-13.
19. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
20. Lee JK, Sayers TJ, Brooks AD, et al. IFN-g-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000;164:231-9.
21. Peshes-Yaloz N, Rosen D, Sondel PM, Krammer PH, Berke G. Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 2007;120:502-11.
22. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW. Effector cell-derived lymphotoxin α and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 2004;64: 406-14.
23. Brossart P, Bevan MJ. Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med 1996;183:2449-58.
24. Cao W, Tykodi SS, Esser MT, Braciale VL, Braciale TJ. Partial activation of CD8+ T cells by a self-derived peptide. Nature 1995;378:295-8.
25. Kessler B, Hudrisier D, Schroeter M, Tschopp J, Cerottini JC, Luescher IF. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. J Immunol 1998; 161:6939-46.
26. Kojima H, Toda M, Sitkovsky MV. Comparison of Fas- versus perforin-mediated pathways of cytotoxicity in TCR- and Thy-1-activated murine T cells. Int Immunol 2000;12:365-74.
27. Esser MT, Krishnamurthy B, Braciale VL. Distinct T cell receptor signaling requirements for perforinor FasL-mediated cytotoxicity. J Exp Med 1996;183: 1697-706.
28. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-γ-and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008;118:1398-404.
29. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62.
30. Shanker A, Brooks AD, Tristan CA, et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 2008;100:649-62.
31. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigenspecific T cell function during tumor progression. J Exp Med 2004;200:1581-92.
32. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 2006;176:3374-82.
33. Shanker A, Verdeil G, Buferne M, et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007; 179:6651-62.
34. Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180:163-70.